The most successful anti-tumor HDAC6 inhibitors to date are ACY-1215 (47) and ACY-241 (48), which are oral selective HDAC6i under clinical investigation for the treatment of refractory multiple myeloma (MM). This evidence concerns the gene HDAC6 and plasma cell myeloma.